Cargando…

Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer

OBJECTIVE: To define a predictive factor for pathologic complete response, compare the oncologic outcomes associated with the degree of pathologic response after neoadjuvant chemotherapy, and to analyze pathologic complete response as a prognostic factor for overall survival and progression-free sur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silva, Luana Carolina Ferreira Fiuza, de Arruda, Lilian Silva Martins, David, Waldec Jorge, Cruz, Felipe José Silva Melo, Trufelli, Damila Cristina, del Giglio, Auro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355205/ https://www.ncbi.nlm.nih.gov/pubmed/30673053 http://dx.doi.org/10.31744/einstein_journal/2019AO3434

Ejemplares similares

Complete pathologic response as a prognostic factor for squamous cell carcinoma of the oropharynx post-chemoradiotherapy()
por: Trufelli, Damila Cristina, et al.
Publicado: (2015)

Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy
por: Normando, Sávia Raquel Costa, et al.
Publicado: (2018)

Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice
por: de Matos, Leandro Luongo, et al.
Publicado: (2010)

From one side to the other: what is essential? Perception of oncology patients and their caregivers in the beginning of oncology treatment and in palliative care
por: Munhoz, Bruna Antenussi, et al.
Publicado: (2014)

The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms
por: Matos, Leandro Luongo, et al.
Publicado: (2015)

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: de Freitas, Ana Julia Aguiar, et al.
Publicado: (2021)

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

High mortality among patients with cancer and COVID-19 infection: the experience of a Brazilian cancer center
por: Barros, Lilian Arruda do Rêgo, et al.
Publicado: (2021)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma()
por: Crusoé, Edvan de Queiroz, et al.
Publicado: (2021)

Mammographic and Ultrasonographic Imaging Analysis for Neoadjuvant Chemotherapy Evaluation: Volume Reduction Indexes That Correlate With Pathological Complete Response
por: Mello, Juliana M, et al.
Publicado: (2022)

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
por: Pennisi, Angela, et al.
Publicado: (2016)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
por: de CASTRO, Juliana Silveira Lima, et al.
Publicado: (2021)

Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
por: Lee, In Hee, et al.
Publicado: (2020)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer
por: Zhang, Qi, et al.
Publicado: (2021)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

Paullinia cupana for control of hot flashes in breast cancer patients: a pilot study
por: Oliveira, Saulo Silva, et al.
Publicado: (2013)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
por: Lejeune, Marylène, et al.
Publicado: (2023)

Study of otoacoustic emissions during the female hormonal cycle
por: Arruda, Priscila Oliveira, et al.
Publicado: (2015)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes
por: Huang, Liang, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1j46jgjhdfh0nbogaa4upbkqo5